V10: Therapeutic radiopharmaceuticals

Pharmacometric modeling notes for ATC V10, therapeutic radiopharmaceuticals.

Modified

September 22, 2026

Mechanistic extrapolation. PBPK has been applied in radiopharmaceutical therapy to predict time-integrated activity for treatment planning [1,2].

References

[1]

Kletting P, Maaß C, Reske S, Beer AJ, Glatting G. Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy. PLOS ONE 2015;10:e0127934. https://doi.org/10.1371/journal.pone.0127934.

[2]

Hardiansyah D, Begum NJ, Kletting P, Mottaghy FM, Glatting G. Sensitivity analysis of a physiologically based pharmacokinetic model used for treatment planning in peptide receptor radionuclide therapy. Cancer Biotherapy and Radiopharmaceuticals 2016;31:217–24. https://doi.org/10.1089/cbr.2016.2012.